Call 1 (888) 460-6556 to speak with a counselor.

In developed countries around the globe, the standard of care for opiate addiction is what’s known as “medically assisted treatment.” Under a doctor’s supervision, people with addictive disorders are prescribed medications like methadone, buprenorphine and Suboxone, which remove the cravings associated with opiate addiction.

In the U.S., however, by far the most common form of treatment is based around the concept of strict abstinence. Advocates of the abstinence model consider the use of Suboxone or methadone to be tantamount to using heroin itself. Many in the medical establishment oppose the abstinence model — as do officials at the Centers for Disease Control and Prevention and the Substance Abuse and Mental Health Administration — and a recent Huffington Post investigation found t…

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Call 1 (888) 460-6556 to speak with a counselor.

Updated Date: Feb 11, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

The Untapped Potential of Office-Based Buprenorphine Treatment

February 10, 2015

Opioid abuse and dependence are reaching epidemic proportions in the United States, resulting in a staggering number of overdose deaths and economic costs that exceed $56 billion annually. Medication-assisted therapies, such as buprenorphine (Suboxone) and methadone, represent the most efficacious treatments for opioid dependence. Office-based buprenorphine treatment is especially well positioned to provide a rapid […]

Read the full article →

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

February 10, 2015

Conclusions There was no clinically meaningful impact of boceprevir on methadone or buprenorphine pharmacokinetics, suggesting that methadone/buprenorphine dose adjustments are not required upon coadministration with boceprevir. Individual patients may differ in their clinical experience and clinicians should maintain vigilance when coadministering these medications. (Source: European Journal of Clinical Pharmacology) MedWorm Sponsor Message: Directory of the […]

Read the full article →

Past-year gambling behaviour among patients receiving opioid substitution treatment

January 26, 2015

Conclusions: Gambling participation of the OST patients seemed to be somewhat similar compared with the Finnish general population, but gambling problems were more common among OST patients. Gender and age may not be very strong indicators of risk while screening problem gamblers among OST patients. Institution of a problem gambling screening program is recommended, and […]

Read the full article →

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

January 20, 2015

Conclusions Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in […]

Read the full article →

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

January 9, 2015

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277. PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry) MedWorm Sponsor Message: Directory of the best January Sales in the […]

Read the full article →

Complete Care Medical Center Now Offering Same Week Appointments for…

December 29, 2014

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best […]

Read the full article →

ZUBSOLV (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet, Orally Disintegrating [Orexo US, Inc.]

December 24, 2014

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone

December 18, 2014

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →